paper_id,claim,figure_id,title,caption,local_image_path,url
PMC11000212,"The buprenorphine taper lasted until the second day of stable buspirone phase, as illustrated with the dashed line.Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",PMC11000212_figure_2,,CONSORT Flow Diagram,./data/PMC11000212/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69a8/11000212/872ec6080830/nihms-1874889-f0003.jpg
PMC11000212,"For Bone and Muscle Aches, Perspiring, Restlessness, Twitching, Tearing Eyes, and Yawning scores were not statistically different during the buspirone titration phase but differed by medication condition during stable buspirone in phase Week 1, 2, or both (Figure 2, Panels B–I).",PMC11000212_figure_2,,CONSORT Flow Diagram,./data/PMC11000212/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69a8/11000212/872ec6080830/nihms-1874889-f0003.jpg
PMC11000212,"Linear mixed-model analyses where time was defined by phases (titration, stable Week 1, stable Week 2) replicated these findings and revealed significant effects of phase, F(2.0, 249.0) = 40.4, p < .001, and Group × Phase interactions, F(2.0, 249.0) = 11.1, p < .001, but not study group, on SOWS Total scores (Figure 2, Panel A).",PMC11000212_figure_2,,CONSORT Flow Diagram,./data/PMC11000212/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69a8/11000212/872ec6080830/nihms-1874889-f0003.jpg
